Likewise, the upregulation of Trem2 and Apoe, key regulators of microglial activation, suggests that TREM2-targeted therapies, which have shown promise in neurodegenerative disease models [35], may hold therapeutic potential for mitigating neuroinflammatory damage in aging. The gene discussed is APOE; the disease is neurodegenerative disease.